Journal
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
Volume 6, Issue 5, Pages 671-683Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14787210.6.5.671
Keywords
antimicrobial therapy; beta-lactamase; Escherichia coli; extended-spectrum beta-lactamase; Klebsiella pneumoniae; mortality; risk factor
Funding
- Wyeth
- Merck
- Pfizer
- Ministerio de Sanidad y Consumo
- Instituto de Salud Carlos III - FEDER
- Spanish Network for the Research in Infectious Diseases [REIPI RD06/0008]
- FIS [PI070190]
Ask authors/readers for more resources
The spread of extended-spectrum beta-lactamases (ESBLs) in nosocomial and community-acquired enterobacteria is an important challenge for clinicians as the therapeutic options for these organisms are limited. The emergence of ESBL-producing Escherichia coli in the community, associated with the spread of CTX-M ESBL, is one of the most significant epidemiologic changes in infectious diseases during recent years. The epidemiology of these infections is complex and combines the expansion of mobile genetic elements with clonal spread. Infections caused by ESBL producers are associated with increased mortality, length of stay and increased cost. An inadequate empirical therapy for serious infections caused by these organisms is independently associated with increased mortality. Carbapenems are the drugs of choice for serious infections caused by ESBL-producing organisms but their overuse is a cause of concern.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available